Biomarker strategy for late-stage heme assets• Represent translational oncology as a core member of late stage lymphoma clinical project teams: developing biomarker strategies, analyzing clinical biomarker data, supporting biomarker operations. Biomarkers include blood based (flow cytometry, target engagement, ctDNA) and tissue-based (WGS, WTS)• Lymphoma lead for MRD asset workstream• Leading cross-functional teams to evaluate implementation of a novel NHL patient segments• Translational Lead for unblinded MM study team to support dose selection

Non-clinical in vivo study support for a clinical asset seeking approval in the settings of medical countermeasures and in cancer supportive care.

Built and led a team of six, including two PhDs, to conduct translational preclinical research, and to plan for success in developing clinical biomarker strategies.• Supervised and led both internal (1 PhD and 2 technicians) and external in vivo experiments in immuno-oncology, chemo-resistance, and fibrosis• Supervised a PhD bioinformatician to generate hypotheses for patient and indication selection• Supervised in vitro experiments to support hypotheses concerning mechanism of action• Member of the Reseach Leadership Team

Develop and implement clinical biomarker strategies for two T-cell redirecting bispecific programs (one dose-escalation, one candidate) and an antibody-drug conjugate (ADC) (dose-escalation) for solid tumors.• Represent translational oncology as a core member of clinical project teams: developing biomarker strategies, analyzing clinical biomarker data, supporting biomarker operations. Biomarkers include blood based (cytokines, flow cytometry) and tissue-based (nanostring, IHC)• Keep abreast of new technologies for clinical biomarkers• Advise research project teams on experiments that would impact clinical biomarker selection and novel drug combinations

Develop and implement strategies for discovering novel biomarkers for oncology projects, including T-cell redirecting bispecific antibodies and ADCs for solid tumors and for acute myeloid leukemia• Biomarker discovery for late-stage preclinical programs, n of 1 studies in patient-derived xenografts and ADC/IO combinations• Team member to implement external Breadth of Efficacy (BoE) studies• Assess landscape of CROs performing complex in vitro assays, and performing pilot studies to test capabilities, in order to access more relevant systems for translational research

Project Leader for discovery-stage monoclonal antibody projects in immuno-oncology, autoimmunity, and cardiovascular diseases• Developed, executed, and championed project strategy in order to efficiently reach go/no go decision points• Point person within Pfizer to work with and build the relationship with the academic PI• Co-authored proposals with academic PIs for consideration for funding• Supervised 1-2 research associates and mentored academic postdoctoral fellows

Performed target validation for drug discovery and developing RNAi therapeutics• Performed siRNA and shRNA screens up to whole genome for understanding MOA of drug resistance and target discovery in oncology, inflammation, and virology• Tested novel formulations for siRNA delivery and MOA in vitro and in vivo• Developed RNAi tools for DMPK and non-clinical safety

Led 5 FTEs (1 PhD/4 RAs) in discovering and validating novel targets in inflammatory disease and HCV

In vivo pharmacologist for small molecule oncology programs

Developing novel GEMMs for cancer research

Developed RNAi based tools for target validation

Elucidated novel functions of the MRE11/RAD50/NBS1 complex using mouse models and yeast